PROJECT SUMMARY This supplement extends the work proposed in the parental grant that is focused on targeting p53 protein conformational defects for ovarian cancer prevention and treatment. Here, we will test the effects of the administration of a p53 aggregation inhibitor on cancer development using an in vivo HGSOC model carrying control p53 mutations. We will also investigate whether protein aggregation is a broader phenomenon influencing ovarian cancer cell fitness using organoid models.